Author

C. Cullinane

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:cell signaling & trafficking· 2 Research Focus:differential expression· 2 Assay:proteomics· 2

Frequent Co-Authors

J. Kang· 4 shared R. B. Pearson· 4 shared A. S. Trigos· 3 shared E. Sanij· 3 shared G. A. McArthur· 3 shared K. M. Hannan· 3 shared K. T. Chan· 3 shared R. D. Hannan· 3 shared

Activity by Year

2019-2020 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

J. Kang

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

E. P. Kusnadi, A. S. Trigos, C. Cullinane, D. L. Goode, O. S. Larsson, J. R. Devlin, K. T. Chan, D. P. DeSouza, M. J. McConville, G. A. McArthur, G. Thomas, E. Sanij, G. Poortinga, R. D. Hannan, K. M. Hannan, , R. B. Pearson

The paper shows that combining CX-5461 with pathway inhibitors improves efficacy by suppressing metabolic regulators, but resistance arises through translational re-wiring and cAMP pathway activation in blood cancers.

bioRxiv · Mar 26, 2020Cancer Biology

Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer

S. Yan, P. B. Madhamshettiwar, K. J. Simpson, S. Ellis, J. Kang, C. Cullinane, K. E. Sheppard, K. M. Hannan, R. D. Hannan, E. Sanij, R. B. Pearson, K. T. Chan

This study identifies that combining RNA Polymerase I inhibitor CX-5461 with TOP1 inhibitor topotecan enhances DNA damage response and efficacy in high-grade serous ovarian cancer.

bioRxiv · Nov 20, 2019Cancer Biology

RNA binding kinase UHMK1 regulates therapy induced metabolic adaptation in BRAFV600 melanoma

L. K. Smith, T. Parmenter, M. Kleinschmidt, E. P. Kusnadi, J. Kang, C. A. Martin, P. Lau, J. Lorent, A. S. Trigos, T. Ward, A. D. Rao, E. J. Lelliott, K. E. Sheppard, D. Goode, R. J. Hicks, , G. A. McArthur

The paper identifies UHMK1 as a regulator of metabolic adaptation in BRAFV600 melanoma under targeted therapy, showing its role in mRNA transport and translation and its impact on therapy resistance.

bioRxiv · Sep 21, 2019Cancer Biology

Inhibition of RNA Polymerase I Transcription Activates Targeted DNA Damage Response and Enhances the Efficacy of PARP Inhibitors in High-Grade Serous Ovarian Cancer

E. Sanij, K. M. Hannan, S. Yan, X. Xuan, J. E. Ahern, K. T. Chan, J. Son, O. Kondrashova, E. Lieschke, M. J. Wakefield, A. S. Trigos, D. Frank, S. Ellis, C. Cullinane, J. Kang, , R. B. Pearson

This study shows CX-5461, an RNA polymerase I inhibitor, enhances PARP inhibitor efficacy in HR-deficient HGSOC by inducing replication stress and DNA damage, overcoming resistance mechanisms.

bioRxiv · Apr 29, 2019 · PreprintCancer Biology